Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors. Issue 2 (9th December 2020)
- Record Type:
- Journal Article
- Title:
- Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors. Issue 2 (9th December 2020)
- Main Title:
- Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors
- Authors:
- Yap, Desmond Y. H.
McMahon, Lawrence P.
Hao, Chuan‐Ming
Hu, Nan
Okada, Hirokazu
Suzuki, Yusuke
Kim, Sung Gyun
Lim, Soo Kun
Vareesangthip, Kriengsak
Hung, Chi‐Chih
Nangaku, Masaomi - Abstract:
- Abstract: Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard‐of‐care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF‐prolyl hydroxylase inhibitors (HIF‐PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia‐Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF‐PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia‐Pacific region who have clinical experience or have been investigators in HIF‐PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF‐PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF‐PHI, taking into account both available data and expert opinion in areas where evidence remains scarce. SUMMARY AT A GLANCE: The Asian Pacific society of nephrology HIF‐PHI Recommendation Committee summarizes the consensus views of the committee regarding the use of HIF‐PHI,Abstract: Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard‐of‐care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF‐prolyl hydroxylase inhibitors (HIF‐PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia‐Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF‐PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia‐Pacific region who have clinical experience or have been investigators in HIF‐PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF‐PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF‐PHI, taking into account both available data and expert opinion in areas where evidence remains scarce. SUMMARY AT A GLANCE: The Asian Pacific society of nephrology HIF‐PHI Recommendation Committee summarizes the consensus views of the committee regarding the use of HIF‐PHI, taking into account both available data and expert opinion in areas where evidence remains scarce. … (more)
- Is Part Of:
- Nephrology. Volume 26:Issue 2(2021)
- Journal:
- Nephrology
- Issue:
- Volume 26:Issue 2(2021)
- Issue Display:
- Volume 26, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 26
- Issue:
- 2
- Issue Sort Value:
- 2021-0026-0002-0000
- Page Start:
- 105
- Page End:
- 118
- Publication Date:
- 2020-12-09
- Subjects:
- anaemia -- Asian Pacific -- chronic kidney disease -- hypoxia inducible factor -- prolyl hydroxylase inhibitor
Nephrology -- Periodicals
Kidneys -- Diseases -- Periodicals
Nephrologists -- Periodicals
616.61
616.61 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1111/nep.13835 ↗
- Languages:
- English
- ISSNs:
- 1320-5358
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6075.684400
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25870.xml